Israel’s Tiltan Pharma Ltd has begun a Phase II clinical trial of its TL-118 drug for the treatment of pancreatic cancer. The trial will include 80 patients at three Israeli hospitals. TL-118 prevents blood flow to tumours, preventing their growth. Scientists at the Hebrew University of Jerusalem developed the drug.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000724848&fid=1725